US-based biopharmaceutical company Biofrontera has finished enrolling subjects in its multicentre Phase III trial of Ameluz ...

Biofrontera announced the enrollment of the final patient in its Phase 3 clinical trial evaluating Ameluz for the treatment of mild to moderate actinic keratoses on the extremities, neck and trunk.

Biofrontera Inc. has completed enrollment for its Phase 3 clinical trial of Ameluz® photodynamic therapy (PDT), aiming to treat mild to moderate actinic keratoses (AKs) on the neck, trunk ...

FDA approval to use up to three tubes of Ameluz per treatment and the successful Phase 3 study results for treating superficial basal cell carcinoma were identified as major milestones for the ...